Amryt Pharma plc (AMYT)

Etorro trading 970x250
Amryt Pharma plc (AMYT) Logo

About Amryt Pharma plc

Amryt Pharma plc, a biopharmaceutical company, develops and commercializes therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is based in London, the United Kingdom. Address: Dept 920A, London, United Kingdom, N22 8HH

Amryt Pharma plc News and around…

Latest news about Amryt Pharma plc (AMYT) common stock and company :

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
11 Jan, 2022 Yahoo! Finance

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide - Acromegaly patients were exposed to Mycapssa® during the global Open-Label Extension (OLE) of the MPOWERED Phase 3 Trial for a maximum of 3.5 years. - Patients switching from injectable Somatostatin Receptor Ligands (iSRLs) to Mycapssa® during the OLE reported improved

Key Dates for AIM Delisting
06 Jan, 2022 Yahoo! Finance

Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6, 2022, Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“Amryt” or the “Company”), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today reminds shareholders of the key dates concerning the cancellation of the admission of its ordinary shares of nominal value £0.06 each (the “Ordinary Shares”) to trading on AIM (the “A

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
04 Jan, 2022 Yahoo! Finance

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients DUBLIN, Ireland, and Boston MA, January 4, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that The Lancet Diabetes & Endocrinology has published the full results of the global Phase 3 MPOWERED clinic

Total Voting Rights
04 Jan, 2022 Yahoo! Finance

Total Voting Rights DUBLIN, Ireland, and Boston MA, January 4, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on December 31, 2021 the issued share capital of the Company comprised 319,814,747 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights

Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ...
17 Dec, 2021 Yahoo! Finance

Investment company Rubric Capital Management LP (Current Portfolio) buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, Amryt Pharma PLC, Radius Health Inc, sells Kraton Corp, , Tronox Holdings PLC, TTM Technologies Inc, Popular Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rubric Capital Management LP.

Timothy P. Lynch’s Stonepine Capital Portfolio: Top 10 Healthcare Stocks
11 Dec, 2021 Yahoo! Finance

In this article, we discuss the top 10 healthcare stock picks of Timothy P. Lynch’s Stonepine Capital. If you want to skip our detailed analysis of these stocks, go directly to Timothy P. Lynch’s Stonepine Capital Portfolio: Top 5 Healthcare Stocks. Timothy Lynch is the managing member at Stonepine Capital, which is an investment management […]

Director/PDMR Shareholding
30 Nov, 2021 Yahoo! Finance

Amryt Pharma plc Director/PDMR Shareholding The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018). Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them 1Details of the person discharging managerial responsibilities/person closely associated a)Name Ray Stafford 2Reason for the notification a)Positio

Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension
24 Nov, 2021 Yahoo! Finance

Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA to reviewnew data submission.

12 Health Care Stocks Moving In Tuesday's Intraday Session
23 Nov, 2021 FinancialContent

Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 228.5% to $7.26 during Tuesday's regular session. The company's ...

Amryt's Skin Disorder Drug Application Review With FDA Extended By Three Months
23 Nov, 2021 FinancialContent

The FDA made athree-month extension to the review periodforAmryt Pharma Plc's(NASDAQ: AMYT) Oleogel-S10 ...

The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
23 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
23 Nov, 2021 FinancialContent

Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 157.46% to $5.69 during Tuesday's pre-market session. ...

Amryt Provides Update on Regulatory Review Process for Oleogel-S10
23 Nov, 2021 Yahoo! Finance

Amryt Provides Update on Regulatory Review Process for Oleogel-S10 FDA PDUFA goal date extended by three months to February 28, 2022 EMA CHMP opinion now expected in January 2022 DUBLIN, Ireland, and Boston MA, November 23, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the US Food and Drug Administration (“FDA”) has extended the review peri

12 Health Care Stocks Moving In Monday's Pre-Market Session
22 Nov, 2021 FinancialContent

Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's ...

Amryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
22 Nov, 2021 Yahoo! Finance

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“UK MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION IN WHICH THE SAME WOULD BE A VIOL

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Tops Revenue Estimates
03 Nov, 2021 Yahoo! Finance

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 66.67% and 7.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Amryt Reports Strong Q3 2021 Results
03 Nov, 2021 Yahoo! Finance

Amryt Reports Strong Q3 2021 Results 14.6% YoY revenue growth in Q3 to $56.5M 21.5% growth in metreleptin revenues YoY to $36.3M in Q3; 51.6% growth YoY excluding the impact of sporadic LATAM orders 7th consecutive quarter of positive EBITDA generation excluding Chiasma transaction costs Cash of $123.2M at September 30, 2021 Reaffirming FY 2021 revenue guidance to $220M - $225M, representing 20-23% YoY growth Conference call and webcast today at 0830 EDT / 1230 GMT DUBLIN, Ireland, and Boston MA

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
02 Nov, 2021 FinancialContent

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for ...

Earnings Preview: Amryt Pharma PLC Sponsored ADR (AMYT) Q3 Earnings Expected to Decline
28 Oct, 2021 Yahoo! Finance

Amryt Pharma PLC Sponsored ADR (AMYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
20 Oct, 2021 Yahoo! Finance

Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3 DUBLIN, Ireland, and Boston MA, October 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the third quarter 2021 will be released on Wednesday, November 3, 2021 at 0700 EDT/1100 GMT. Amryt will host a conference call and webc

Amryt Announces New Patents for Oleogel-S10 and Mycapssa®
19 Oct, 2021 Yahoo! Finance

Amryt Announces New Patents for Oleogel-S10 and Mycapssa® DUBLIN, Ireland, and Boston MA, October 19, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its lead development candidate, Oleogel-S10, and its recently acquired and third commercial product, Mycapssa®. Oleogel-S10 The United States Patent and Trademark Office

10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital
14 Oct, 2021 Yahoo! Finance

In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. If you want to skip our detailed analysis of Stonepine Capital’s history, investment philosophy, and hedge fund preference, go directly to 5 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital. Timothy Lynch is […]

20 Stocks Moving in Tuesday's Pre-Market Session
14 Sep, 2021 FinancialContent

Gainers Communications Systems, Inc. (NASDAQ: JCS) rose 34.8% to $9.15 in pre-market trading as the company declared a special ...

Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
13 Sep, 2021 Yahoo! Finance

Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M Representing 20% - 23% YoY growth Virtual Capital Markets Event today at 1000-1200 EDT DUBLIN, Ireland, and Boston MA, September 13, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is today pleased to announce the raising of Amryt’s current full year 2021 revenue guidance. Given the recent acquisition

Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021
19 Aug, 2021 FinancialContent

Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ:PAYS) was changed from Neutral to Buy. In ...

Amryt Issues Ordinary Shares and Total Voting Rights
19 Aug, 2021 Yahoo! Finance

Amryt Issues Ordinary Shares and Total Voting Rights DUBLIN, Ireland, and Boston MA, August 19, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that as part of the acquisition of Chiasma, Inc. (“Chiasma”) by Amryt on August 5, 2021, (the “Transaction”) and further to the announcement on such date, Amryt will issue 7,015 additional new ordinary shares as

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
18 Aug, 2021 FinancialContent

Gainers PharmaCyte Biotech (NASDAQ:PMCB) shares rose 71.92% to $5.88 during Wednesday's pre-market session. The ...

22 Stocks Moving in Wednesday's Pre-Market Session
18 Aug, 2021 FinancialContent

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares rose 50.6% to $23.12 in pre-market trading. Virpax Pharmaceuticals ...

Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
09 Aug, 2021 Yahoo! Finance

Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT DUBLIN, Ireland, and Boston MA, August 9, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, will host a Virtual Capital Markets Event for Analysts and Investors on Monday, September 13, 2021, from 1000 – 1200 (EDT). Presentations will include an update on Amryt’s long-term strategy, the global

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Amryt Pharma plc (AMYT) is a NASDAQ Common Stock listed in , ,

970x250